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Abstract The stages of change (SOC) theory suggests
individuals adapt incrementally to behaviors like adherence,
requiring different strategies over the behavior change con-
tinuum. Offering financial incentives (FIs) is one strategy to
motivate adherence. This qualitative sub-study examined
adherence barriers and the role of FIs to increase viral sup-
pression (VS) among HIV Prevention Trials Network
(HPTN) 065 study participants categorized into SOC-related
adherence stages based on changes from baseline to follow-
up viral load tests. Of 73 participants, most were in Main-
tenance stage (n = 31), defined as having achieved VS
throughout HPTN 065, or in Action stage (n = 29), defined
asmoving fromvirally unsuppressed to suppressed in 50%or
more of tests. Only 13 were Low Adherers, having achieved
VS in fewer than 50% of tests. The latter group faced sub-
stantial social and structural adherence barriers. Participants
in the Action stage made positive changes to adherence
routines to achieve VS. Those in Maintenance were less
incentivized by FIs, as they were already committed. Results
from this sub-study suggest FI effectiveness may vary across
the SOC continuum, with greatest impact for those initiating
antiretroviral orwithout explicit adherence routines. FIsmay
be insufficient to overcome strong social or structural bar-
riers, and unnecessary for those intrinsically committed to
remaining adherent.
Keywords Adherence  Stage of change  Financial
incentives  HIV  United States
Introduction
The HIV Prevention Trials Network (HPTN) 052 study
demonstrated that antiretroviral (ART) therapy dramati-
cally reduces the risk of transmission of HIV among sero-
discordant couples [1]. This finding and the results of the
START study, which demonstrated benefit from early ART
initiation, motivated a revision of ART treatment guideli-
nes to recommend ART for all HIV-infected individuals
[2–4]. Improvements in medication regimens, reducing the
number of pills and their toxicity, have facilitated patients’
adherence. Nevertheless, studies suggest that many patients
do not achieve optimal adherence [5–8].
The stages of change (SOC) model (Fig. 1) has been
applied previously to explain and/or predict ART medica-
tion adherence behaviors [9–13]. It posits that individuals
adapt incrementally to new, complex behaviors like ART
adherence by moving from early stages of contemplating
and planning for change to testing out new behaviors and
eventually maintaining the adopted behavior [14]. The
model suggests that individuals may require or make use of
different knowledge, skills and motivations as they move
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from one stage to another. Individuals in pre-contempla-
tion, the first level of behavioral change, are either unaware
of the need for change or do not intend to change their
behavior in the near future, whereas those in contemplation
and preparation phases are actively thinking about—and
then planning for change. To move from pre-contemplation
to contemplation or preparation, knowledge about one’s
risk and the benefits of a therapeutic or preventive behavior
is often a necessary condition, but plays little role in sup-
porting the same individual to maintain a behavior once
enacted. The SOC also suggests that anywhere along the
continuum of behavior change people may relapse to ear-
lier stages (Fig. 1).
Motivation has been identified as a critical element
influencing an individual’s ability to initiate and sustain
behavior change [15]. Whereas intrinsic motivation—un-
dertaking a behavior to improve oneself—has been asso-
ciated with longer-term behavior change [16], external
sources of motivation, including the use of financial
incentives (FIs), has been shown to motivate positive
changes in a range of behaviors [17, 18]. Several studies
have assessed the efficacy of FI to increase ART adher-
ence, with varying results. For example, HIV-infected
patients who experienced a previous treatment failure and
received an adherence case management intervention with
a $20 incentive at each follow-up visit were significantly
more likely to show declines in viral load (VL) and
improvements in immune function compared to those
receiving standard treatment [19]. In contrast, no difference
in viral suppression (VS) was found among HIV-infected
drug users in Chennai, India who received FI [20] nor
among hospitalized patients with HIV infection and sub-
stance use in the US [21]. Several small studies found
initial improvements in ART pill-taking with provision of
FIs, but adherence was not sustained [22–24].
The HPTN 065 (TLC-Plus) study, conducted between
February 2011 and January 2013, evaluated the role of FIs
in increasing VS through increased adherence to ART.
Patients in care and on ART for a minimum of three
months were eligible to receive a $70 gift card no more
than once every 3 months if they were virally suppressed at
their HIV care visits. The study found that the FI inter-
vention increased VS overall with a stronger effect among
participants who were not previously consistently sup-
pressed [25].
Because no individual-level data were collected as part
of the HPTN 065 study [26], a qualitative sub-study was
designed to help interpret the results and explore patient
and provider experiences with FIs. In this paper, we use
changes in individuals’ baseline and follow-up VL test
results to categorize their stage of medication adherence,
examining whether and/or how the effect of FIs differed
along the continuum of ART adherence stages. More
specifically, we examine the role that FI played in helping
participants achieve and/or maintain VS. The paper seeks
to (1) identify what barriers and facilitators were experi-
enced by patients receiving FIs in the HPTN 065 study, (2)
examine whether these barriers and facilitators appeared to
differ by a SOC-based adherence continuum, and (3) assess
what role patients perceived the FI intervention to play in
helping them adhere to their medication.
Methods
We conducted semi-structured interviews with 76 partici-
pants from 14 clinic sites in Washington, DC and the
Bronx, NY who participated in the HPTN 065 study. Sub-
study participants were recruited by site staff after exiting
the main study, following a non-probability, purposive,
Fig. 1 Stages of change
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quota-based sampling strategy, to ensure that the qualita-
tive sub-study included a heterogenous sample of patients
in relation to their baseline VL status (suppressed or
unsuppressed), ART initiation (before or after the study
began) and exposure to FIs (B3 or C5 gift cards). Stan-
dardized talking points were provided to each site for
recruitment. Patients eligible for the sub-study must have
been enrolled in care at the participating site, and eligible
for the HPTN 065 study during at least 15 months of the
24-month intervention. VL test results obtained as part of
the participants’ routine HIV care, beginning several
months prior to study implementation and continuing
throughout the study, and the date of ART initiation, were
abstracted. VS was defined as HIV RNA\400 copies/mL.
The sub-study was approved by the relevant Central or
Local Institutional Review Boards (IRBs) prior to data
collection.1 Written informed consent was obtained from
all participants prior to data collection.
For this analysis, we categorized 73 of the 76 sub-study
participants into 1 of 3 adherence-related categories, based
on change between baseline VS and their VS status over
the course of the study. Baseline VL test results were not
available for three participants. The number of VL tests
across sub-study participants was variable, as the inter-
vention was added to standard HIV care in a clinical set-
ting; thus, there was no study-specific visit schedule to
adhere to, and patients were to continue with their normal
pattern of HIV care visits. Participants who were not virally
suppressed at baseline and on 50% or fewer of their sub-
sequent VL tests were categorized as being in the Low
Adherence stage. Participants were categorized as being in
the Action stage if they had no VS at baseline, but achieved
partial (more than 50% of VL tests with VS) or full VS
(100% of VL tests) during the study. Those who were
already on ART with VS at baseline and consistently
maintained VS over the course of the study were classified
as being in the Maintenance stage. Only 13 of 76 partici-
pants were ART naı̈ve at baseline; we classified those who
achieved more than 50% but less than 100% VS in the
Action stage and those who were fully suppressed at each
follow-up visit in the Maintenance stage (Table 1). In
addition, we examined all 76 participants’ data for infor-
mation about delaying ART initiation after diagnosis and/
or periods off treatment to better understand pre-contem-
plation and relapse stages, as participants often described
themselves in these stages prior to being in the study.
All interviews were conducted in English2 by trained
interviewers after participants had exited the study.
Interviews were audio-recorded and transcribed verbatim.
Transcripts were then uploaded into NVivo 10.0 (QSR
International) and analyzed thematically, following a pro-
cess of reading, coding, data display and data reduction
[27]. Members of the research team read a subset of tran-
scripts to identify initial codes, both structural and emer-
gent, for the dataset. Initial codes included: medication
adherence, HIV testing, diagnosis and acquisition, opinions
of the program, and impact on patient. Once the codebook
was established, a team of analysts applied the codes in an
iterative fashion, double-coding approximately 20% of
patient interviews to assess intercoder reliability, dis-
cussing discrepancies, refining the codebook when inter-
pretations differed, and recoding transcripts when
necessary. Subsequently, two additional members of the
research team read a subset of the transcripts to identify
sub-themes related to medication adherence, which were
then discussed and agreed upon by the sub-study research
team. The two adherence team members then applied the
second level of coding related to medication adherence to
all transcripts, assessing intercoder reliability at several
intervals. Sub-codes included adherence patterns, barriers
to adherence, facilitators of adherence, medication attitudes
and medication motivations.
For each participant group, we developed detailed
memos that described self-perceived adherence patterns,
barriers and facilitators to adherence, intrinsic and extrinsic
motivations to adhere, attitudes towards FI and whether
participants believed that receiving FI affected their
adherence behaviors. Excel matrices included summary
information from the memos (i.e., self-perceived adherence
pattern reflecting high, low or mixed adherence) and
incorporated information on the self-reported year of HIV
diagnosis, HIV medication experiences, adherence barriers,
facilitators, and socio-demographic information.
Ethical Considerations
The qualitative sub-study was approved by the relevant
Central or Local IRBs prior to data collection. Written
informed consent was obtained from all interview partici-
pants prior to data collection.
Results
The median age of participants was 48 (range 14–72) years.
The majority were men (64%) and Black (58%). Approx-
imately one-fourth of the sample were Hispanic (23%);
half of participants self-identified as straight (49%), 40% as
gay, and 10% as bisexual. Overall, participants’
1 The local IRBs reviewing this study were: Albert Einstein College
of Medicine of Yeshiva University IRB, Children’s National Health
System IRB, and George Washington University and Medical Center
IRB. 2 One interview was partially conducted in Spanish.
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characteristics generally resembled those of the larger
sample of all participants exposed to the FI intervention
[25]. However, some differences in socio-demographic and
other characteristics exist across the three SOC adherence
groups. In particular, the Low Adherence stage included a
higher proportion of women and individuals diagnosed as
infants or children than the other two groups (Table 2).
Sub-study participants received between two and eleven
VL tests over the duration of the HPTN 065 study (mean
6.6). Sub-study participants joined the FI intervention with
varying lengths of experience on ART. For example, only
13 of 73 participants were ART-naı̈ve prior to exposure to
the intervention. Greater than half of sub-study participants
described being diagnosed at least a decade ago, some
during the mid-1980s to mid-1990s. Most of the partici-
pants were diagnosed as adults, while four reported that
they were diagnosed as children. About a third of partici-
pants described more recent diagnosis, from 2007 onward.
The timing of and circumstances around HIV diagnosis
were unclear for several participants.
Pre-contemplation
Because all participants had initiated ART prior to or as a
part of the HPTN 065 study, none could be characterized as
in the pre-contemplation stage at the time of enrollment in
the sub-study. Nevertheless, during their interviews about a
third of participants (n = 23) described periods of pre-
contemplation, several months or longer after receiving
their HIV diagnosis when they had not considered going on
ART (Table 2). The majority were diagnosed early in the
epidemic; many described treatment delays of 2 to more
than 10 years. Delays, as portrayed in the quotes below,
were often attributed to fear of taking medications that
were perceived as toxic. In some cases, participants were
also dealing with drug or alcohol addictions or debilitating
illnesses that prevented them from seriously contemplating
taking their medications. Two participants, asked about
when they first started taking HIV medications, described
the following:
I was diagnosed in 1990. I did not start taking med-
ication for about 10 years. So, around 2000 I started
taking medication. And my concern was … I was
concerned about taking any medication. Well, back in
the 90’s, I’ve had friends who have gone through so
much hell taking medication, and I felt that, as long
as I wasn’t sick … as long as I wasn’t sick, I was
going to just prolong it as long as I could. (66-year-
old gay Black man)
Whew, 1992…. That’s when I found out I was pos-
itive…. That’s when that … what medicine was that
that was out back then? What was the name of that
medicine? They was saying it was kind of toxic….
And at that time I was getting high, you know, from
crack, so I wasn’t really taking my medicine. You
know what I’m saying. And I would end up in and out
of the hospital a lot, because I was … you know, I
was getting high off of crack, and then I was getting
high. I’d get my check, I would get high, then I’d get
sick and go in the hospital. And then, it seemed like
every time I went in the hospital, my money would
come. (54-year-old straight Black woman)
Despite important advances in HIV treatment, a number
of participants diagnosed more recently, since 2007, still
reported delays, although these were usually of shorter
duration—from 6 months to 2 years. Recently diagnosed
patients were less likely to attribute their lack of treatment
to the drug regimen directly, but described needing some
time before they could think about taking the medication,
mostly due to shame, denial or depression. A young His-
panic man who was diagnosed around age 21, but who
began treatment several years later described his emotional
outlook at the time of his diagnosis:
Table 1 Sub-study SOC groups and definitions
Definition
SOC group during study
Maintenance ART-naı̈ve at baseline and 100% VS during follow-up or on ART with VS at baseline and 100%
VS over the course of the study
Action ART-naı̈ve at baseline and C50% but\100% VS over course of study; or on ART but not VS at
baseline, but from 50 to 100% VS over the course of the study
Low Adherera ART-naı̈ve or on ART but not VS at baseline and\50% of viral load tests suppressed over the
course of the study
SOC categories experienced by all participants
Pre-contemplation Discussions about delaying ART treatment after HIV diagnosis from any sub-study participant
Relapse Discussions about stopping ART treatment from any sub-study participant
a This group is similar to contemplation because they have not fully actualized adherence behavior
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Mean age 44.1 37.8 44.7 45.3
Gender % (n) % (n) % (n) % (n)
Male 64 (47) 31 (4) 62 (18) 81 (25)
Female 33 (24) 62 (8) 34 (10) 19 (6)
Transgender (further information not collected) 3 (2) 7 (1) 4 (1) 0 (0)
Sexual identity
Straight 49 (36) 86 (11) 51 (15) 32 (10)
Gay 40 (29) 7 (1) 34 (10) 58 (18)
Bi-sexual 10 (7) 7 (1) 0 (0) 6 (2)
Don’t know 1 (1) 0 (0) 15 (4) 3 (1)
Race
Black 58 (42) 69 (9) 62 (18) 48 (15)
White 16 (12) 0 (0) 17 (5) 23 (7)
Not reported 26 (19) 31 (4) 21 (6) 29 (9)
Ethnicity
Hispanic 23 (17) 23 (3) 21 (6) 26 (8)
Non-Hispanic 77 (56) 77 (10) 79 (23) 74 (23)
Education levels
Some or no high school 31 (23) 54 (7) 38 (11) 16 (5)
High school/GED 25 (18) 23 (3) 21 (6) 29 (9)
Some college or associate degree 34 (25) 23 (3) 34 (10) 39 (12)
Bachelor’s degree or higher 10 (7) 0 (0) 7 (2) 16 (5)
Income
$10,000 or less 52 (38) 77 (10) 59 (17) 35 (11)
[$10,000\/=$40,000 29 (21) 23 (3) 34 (10) 26 (8)
[$40,000\/=$80,000 12 (9) 0 (0) 4 (1) 26 (8)
[$80,000 5 (4) 0 (0) 0 (0) 13 (4)
Missing 1 (1) 0 (0) 4 (1) 0 (0)
ART naı̈ve at baseline 18 (13) 0 (0) 14 (4) 29 (9)
% of follow-up VLs suppressed 85 37 89 100
Mean # of gift cards received 5.1 2.1 5.4 6.0
Behavioral characteristics (based on qualitative analysis)
When diagnosed
At least 20 years ago (1980s–1992) 22 (16) 23 (3) 17 (5) 26 (8)
Some time ago (1993–2006) 36 (26) 31 (4) 38 (11) 35 (11)
Recently (since 2007) 34 (25) 38 (5) 38 (11) 29 (9)
Unclear 8 (6) 8 (1) 7 (2) 10 (3)
Diagnosed as an infant/child 10 (7) 31 (4) 3 (1) 6 (2)
Pre-contemplation: described delay initiating ART 31 (23) 16 (2) 34 (10) 35 (11)
Ever relapsed 22 (16) 31 (4) 24 (7) 16 (5)
Adherence problems experienced (past/present)
Pill-related (memory, side effects) 49 (36) 69 (9) 52 (15) 39 (12)
Psychosocial (stigma, depression, stress) 30 (22) 46 (6) 31 (9) 23 (7)
Structural (insurance, housing, drugs, jail) 23 (17) 38 (5) 28 (8) 13 (4)
Any current adherence problems 52 (38) 85 (11) 55 (16) 35 (11)
Expressed intrinsic motivation 91 (67) 92 (12) 93 (27) 90 (28)
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Cause the way I found out was an awkward situation.
It was right after my 21st birthday – like literally right
after. It was two guys that I was messing around with
at the time and usually I was like never really like
that. […] And it just seemed like the one slip or the
one particular time kind of like screwed me over for
life…. I felt like the sky was falling. I felt like the
walls were caving in. It was a very dark period for
me. (26-year-old gay Hispanic man)
Similarly, a 30-year-old mother of two who began ART
within the context of the study explained:
When I found out I had to start taking medicine it was
a big shocker for me because, it was like… I wasn’t
in denial about my illness but suddenly everything
became real, because knowing you have an illness
and not feeling certain symptoms and now taking the
pills is like a reminder every, every day. So it was
very hard for me. I went back and forth with my
doctor, letting her know I was having some trouble
with, with coming to terms in taking the medicine.
So, she actually prescribed it and I didn’t take it for
about two months and a half… So I told my doctor
like you know maybe they should start like a program
to prepare patients who don’t take medicine right
away because I was very depressed. (30-year-old
straight woman whose race was not reported)
Low Adherence Group
Of 13 participants classified in the Low Adherence Group,
two-thirds were women and four had been diagnosed with
HIV as infants or young children, and just over half
(n = 7) had been on medication for a decade or more.
All participants in the Low Adherence Group described
their own adherence as mixed or low. They admitted to
forgetting pills and some described being willfully non-
adherent at times. For example, when asked how long she
had been taking her HIV medication, a young transgender
person responded:
I had them ever since I was 18 because that’s when I
found out. But I took them a couple of times, then
they started making me feel sick. I didn’t like that. So
I recently started taking… so I’m like this person, I’m
off and on. So I’ll start it and then stop it. […] So last
year I got Complera, the one pill, and it is amazing.
So I take it every night. I was undetectable in
December, and for… December, January, and
February, I was taking it. I stopped in the middle of
February, and I started back last week… last Monday.
So that’s how I am, but I’m … I’m continuing to be
on it. (23-year-old straight Hispanic transgender
woman)
Many in this group attributed their difficulties with
adherence to depression or sadness often related in some
way to relationship issues. Some experienced on-going
challenges with drug, alcohol use or sexual risk behaviors.
In addition to their current struggles with adherence, four
of the nine participants diagnosed as adults described one
or more periods of relapse in the past. For example, a
middle-aged single Black woman, who acquired HIV from
her partner of 4 years, continued to face setbacks when she
remembered how she became infected. She said:
And I try to take care of myself [the] best way I know
how. Sometimes I do forget my medication because
I’m so busy all over the place, but when I do take it I
make sure I take it. You know, I try to take it every
day. I try not to miss a day. But sometimes when
you’re very, very busy – cause at one time I just sat
home, I would not take the medication, I’m a tell you
that. I don’t know if I was, I don’t know what my
mental state was at that time and I really believe that I
just didn’t care. Because I just couldn’t come to grips
of why that man would do that to me. (48-year-old
straight Black woman)
The words of a 57-year-old mixed-race Hispanic man
conveyed a continuing sense of guilt and stress that appears
to affect his ability to adhere to his medication.
Interviewer: Really, why didn’t you want to take
them?
Participant: Tough with me, ‘cause I did it to myself.
Ain’t nobody pushed me, I wish I would have known, I











Motivated by FI to change behavior 23 (17) 23 (3) 38 (11) 10 (3)
Found FI to be a nice reward 27 (20) 8 (1) 48 (14) 16 (5)
Uses adherence aids 70 (51) 69 (9) 79 (23) 61 (19)
a Includes two current relapsers who moved from VS to 57 and 71% of tests being virally suppressed
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Interviewer: And you were taking them before?
Participant: Right, so the only thing is, I was like
skipping one day, taking them a week, and skipping a
Sunday…
Interviewer: So, how do you think the gift card pro-
gram changed that?
Participant: Well, when I knew about the gift card, I
was on top. I had stopped taking medication. It
wasn’t because of the gift card. It was because things
were going on and, and it’s like stress. (I’m) Really
aggravated at myself sometimes. I’m always by
myself. (57-year-old straight Hispanic man)
Only one Low Adherer linked the potential to earn gift
cards as an incentive to be more adherent. Most participants
in the Low Adherence Group (n = 9) did not identify any
role of the FI in incentivizing adherence. Several (n = 3)
suggested that while the FI didn’t change their adherence
much, it was a nice thing to receive some extra cash.
Well, I was taking it regularly and I mean, you know,
I guess the impact that it had was you know like an
extra seventy bucks or whatever the case was. But I
mean, you know, it wasn’t something where I was
taking the medicine because of the gift card. I mean,
you know, I was working and stuff like that so money
wasn’t really an issue. I guess it was just like, you
know, an extra seventy bucks so why not do it? (26-
year-old gay Hispanic man)
Although the misuse of the gift cards was reported
uncommonly, one participant admitted that he had tried to
use the card to support his drug habit. He explained:
I was acting up crazy, I was losing… you know what
I’m saying? I was trying to figure how I could get over
and get another card, and sell it, and get high again, you
know what I’m saying? So I go, they shut me right
down. I was glad. (58-year-old straight Black man)
Participants in the Low Adherence Group reported that,
more important than the FI, the support of family and
friends—and sometimes the admonitions of providers and
others—reminded them to think about their medications.
As one woman, who attributed her struggles with adher-
ence to deep depression, described:
I was talking to my doctor and she was so mad with
me. She said, ‘Sometimes it goes up and sometimes it
goes down. You ain’t taking your medication.’ I said,
‘For real I don’t like taking the medication, I really
don’t.’ Then she said, ‘Please just try to take this
medication.’ (47-year-old straight Black woman)
Although ‘‘rough’’ on her, she appreciated the consistent
care provided by the clinic staff who used to ‘‘sit [her]
down all the time’’ to explain how medication adherence
related to VL and to help her strategize ways to become
more adherent.
Action Group
About two-fifths of sub-study participants (n = 29) were
either ART-naı̈ve (n = 4) or not virally suppressed
(n = 25) at baseline, but had VS in the majority or all VL
tests conducted during their follow-up visits after the FI
were initiated. Almost all assessed themselves as being
good or even excellent adherers currently, but acknowl-
edged that adherence could still be a challenge. Unlike
those in the Low Adherence Group, these participants
reported that small lapses strengthened their resolve. As
one participant explained:
Well, I want to sustain it [my low viral load]. That’s
why I continue to take it without having any prob-
lems. There are some times when I miss a dosage,
especially at night. I feel bad about that. But I just do
the next day and… after I come to the clinic and they
do the blood and they find out that I’m still non-
detectable, [it] makes me feel good…. I may fall
asleep before it’s time. Then I wake up in the middle
of the night and say, well I’ll just start again the next
day. (58-year-old gay Black man)
Similarly, a 54-year-old gay Black man explained:
Now, it’s like clockwork. In the morning, I’ll take my
medicine. In the evening, I’ll take my medicine. Two
times I had the medication. Two times.’’
Half of participants in the Action Group had been
diagnosed 10 or more years before. Many faced significant
barriers to ART use in the past; HIV-related fear and
stigma prevented some from disclosing their illness or
seeking treatment, and others found the number of pills and
severity of side effects to be daunting. For some, having
navigated these earlier challenges made it easier to adhere
to their current medications. A 48-year-old gay White man
reflected on those earlier days:
My experience with them has changed, because
they’ve gotten more tolerable and more … easier …
easier to take, fewer pills and many fewer side effects
that are visible… Side effects from pills when they’re
bad were horrible.
Others in the Action Group had been diagnosed more
recently. Several ART-naı̈ve patients suggested that tran-
sitioning to ART was more difficult for them than the
diagnosis itself.
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I felt like it was annoying. It was like I went from
taking no pills to taking like this one pill and it was
like, I don’t know. I didn’t like taking it because I had
to make sure I took it every day. Then like I had like
these really dumb side effects like really differ-
ent….Because it’s a big adjustment to take pills every
day when you are not use to taking any pills because
like sometimes you forget. […] Like sometimes, I
take them in the morning so like if I forget until like
night, it’s almost morning again. So I be like, if I take
one now and one in the morning, I feel like I’m
overdosing. (18-year-old gay Black man)
More than a third of the Action Group (n = 12) reported
that they were motivated to be or to remain ‘‘unde-
tectable’’. Having ‘‘undetectable’’ VL was both a sign of
health and an indication of good behavior, even when some
participants did not fully comprehend how being ‘‘unde-
tectable’’ was determined.
Because I know I’m not going to be 100% but when I
get to undetectable, where I get the benefit, that’s
priceless. So I said you know what? To whom much
is given much is required. Take a little bit of extra
time, go back and do that. (54-year-old gay Black
man)
I’m undetectable. And that’s the viral load…. I didn’t
want to know too much about it, but then as I, as I
started taking the (medicine), and I was like I want to
know more about it. So, that makes me feel good that
I’m on it. (38-year-old bisexual Black woman)
The majority described strong intrinsic motivations to
take their medications. They wanted to ‘‘stay healthy’’ or
‘‘to live’’ either for themselves or, for some, for their own
children or grandchildren. One difference between those
who did and did not achieve 100% VS over time appeared
to be the degree to which they accepted ART as a part of
their lives. Most suggested that ‘‘it is no big deal’’. One
patient considered himself ‘‘blessed’’ to be able to take the
medication.
The majority of participants in the Action Group had
adopted explicit strategies to facilitate better adherence.
For example, almost half of the group described making
specific changes to their routines to support their adher-
ence. This included changing the timing or the way they
took their medications, setting alarms or using pill boxes.
I take it like aspirin. Because I have one of those
7-day pill boxes. It’s a big one. I got it from [the
nurse] here at the clinic. It has AM and PM and see I
take anti-depressants. I also take another, I take
something for prostate, I just can’t remember all the
stuff and another antibiotic for HIV-positive people
so you don’t get like thrush, things like that. I just
take them like I was taking… I just take them every
day like I’m supposed to, that’s it. First thing when I
get up in the morning, I have a little something to eat,
I take my morning pills and at night, usually after I
have dinner, I take my evening pills. I do that every,
single day. I don’t even think anything about it. It’s
just what I have to do and I do it. (60-year-old
bisexual White man)
A young married, Black woman reflected on the changes
she had made to become more adherent, saying:
Well when I first started taking it, honestly, I didn’t
take it serious like how I do now. Yeah, I didn’t. I
have an alarm now that I set to take it so I don’t miss.
Back then it was like I tried to put it out my head,
because, you know, being diagnosed with that is not
easy. (22-year-old straight Black woman)
Finally, most participants (n = 25) in the Action Group
found FIs to be motivating to achieve adherence. Most
were clear about the importance of taking their medications
as they were prescribed. But, many also indicated that
remaining adherent was hard, and FIs made it a little easier.
They described it as an incentive, a reward or an extra
nudge. For 11 participants, FIs had an even stronger
influence on adherence. For example, a 50-year-old straight
Black man explained:
I think the card program too, even though you’re sick,
it still helps you to push yourself to do it, to take your
meds to try to stay undetected with you, with the card
or without the card. But after a while with the card,
you realize you could do it if you getting the card or
not. But the card helps start that force of you pushing
yourself.
Maintenance Group
Two-fifths of the participants in the sub-study were already
on ART and virally suppressed at the time they entered the
HPTN 065 study (n = 31). All but one participant in this
group described a high level of commitment to being
adherent to their medication currently—even when it
meant overcoming barriers. They made declarations like
‘‘It doesn’t control me’’; ‘‘I still keep taking my medicine
no matter what’’, and ‘‘I know what I got to do.’’ Most
appeared to have committed themselves to the process of
adhering to treatment. They described filling their own pill
boxes, arranging their schedules to accommodate pill-tak-
ing, and finding ways to take their pills even when away
from home. For example, a participant asserted:
I, my decision to go ahead and start taking the
medications was an informed decision. It wasn’t a
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decision out of panic, it wasn’t a decision because
‘the doctor said so’, I was informed because I did my
research. I felt like, this, they’re gonna give me one
pill, one pill a day. I can do that, I already know about
the Atripla, what’s in it, I can live with that. Let’s go
ahead and do it, so it was an informed decision. (49-
year-old gay Black man)
Others described similarly high levels of commitment.
I know that I need to take it first thing in the morning.
I know I can’t take it on an empty stomach. You
know, I have to eat breakfast, so it’s easy for me to
develop a regimen for myself. So it becomes natural.
(66-year-old gay Black man)
I always carry my pills in my pocket. …Well, you
know what? I’m … I’m very … very picky when it
comes to stuff…. I have this thing of taking it 12
midnight, 12 afternoon, 12 midnight, 12 afternoon.
So I know that when 12 o’clock hits, or 12 afternoon
like today, I have in my pocket, get a glass of water,
drank it, take my pills, I’m good. So I already have
this thing of carrying them on me if I’m going out.
(33-year-old gay Hispanic man)
At least half of patients used words like ‘‘habit’’ or
‘‘routine’’—equating adherence to ART with ‘‘taking a
daily vitamin’’. In his exchange with the interviewer, a
38-year-old gay Black man describes his no-excuses
approach:
And, like I said, it’s become habitual, so I don’t even,
you know …Think about it? When that time sets, it’s
like, okay, get this done and move on, you know?
[…] So, I, listen, wherever I’m at, if it’s time, it’s
time. It’s going down, right there.
This combination of commitment and habit is apparent
in the words of a 55-year-old gay White man as well:
It’s like shaving… you have to do it every single day,
but sometimes you just don’t feel like dragging a
metal blade across your face because you know
you’re going to have… it’s going to be raw, and it’s
going to hurt your face. Same as HIV medications,
you know you have to take them, but, you know, is
this the day that the HIV medications upset my
stomach, or is it not? I mean even after 25 plus years
of taking the medications, I occasionally have side
effects, so you know… so that’s how I equate it…
Routine… knowing that I wake up in the morning, I
eat something. I take my medications.
Almost all participants in the Maintenance Group
described using at least one, but often multiple, adherence
aids to support their adherence behavior. Most common
was establishing a routine around taking their medications
(n- = 12). Additionally, a number of participants (n = 8)
specifically mentioned using pill boxes, phone alarms or
other techniques.
To a greater extent than in the other groups, participants
in the Maintenance Group tended to reflect on the barriers
they had overcome—the positive changes in their medi-
cation regimens and consequently the positive feelings they
had about their regimens. Many also identified how the
love and support of others around them—from family
members, sexual partners and healthcare providers—
helped keep them focused on being adherent. A 51-year-
old man reflected on the acceptance and support his family
extended to him, when he returned home one holiday after
having contracted HIV.
Well, they … they didn’t know for years that I was
HIV (positive) until I got sick, you know. Then my
sister, you know, she [noticed] the way I looked, and
I didn’t think she would talk to me. You know, I
didn’t want to come, you know. So, I came to visit for
the holiday, Christmas. They didn’t want me to go
back. So, we went back, packed up my stuff, you
know. She made me, you know, ‘Here’s your medi-
cine.’ Every day, and, you know, ‘Take care of it.’
you know. And they all knew – all my family
knew…. The fact that now, there’s more people I
know who are on meds. You know, it’s like I’m not
alone doing this. … It’s like a support group, you
know, that helps, you know. (51-year-old gay His-
panic man)
Several women in this group talked about the important
role their husbands or partners played in reminding them
about taking their medication. For example, a 56-year-old
married woman explained:
My husband’s like ‘Did you take your medicine
today?’ ‘Yes I took my medicine.’ He’s such a
wonderful man. ‘Did you take your medicine?’ And I
say ‘I took my medicine.’ He gets checked. We don’t,
I mean we’re older now you know what I’m saying
but- and I tell him every three months he gets
checked. (56-year-old straight woman whose race
was not reported)
None of the participants in the Maintenance Group
expressed negative attitudes towards FIs. The majority felt
that it was good to provide FI, especially for those who had
a problem adhering. They thought it was ‘‘a good idea for
kids, especially kids who […] don’t learn to take their
medicine’’ or for those who ‘‘deviate away from the drug
use, or lack of self-preservation and self-esteem.’’ How-
ever, only a small number (n = 3) felt that FIs helped them
improve their adherence. They tended to describe the
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program as ‘a nice incentive’ for something they were
already doing. About half of the group (n = 16) were clear
that their intrinsic motivation and having integrated med-
ications into their daily routine—and not the FI—drove
their own adherence.
No. I told you I would’ve done it without the gift
cards…. I just know to take my medicine that’s all.
I’ve been going through this for many years now, I
should be used to the grind, you know? (56-year-old
straight Black man)
The gift card, you know, didn’t drive me, you know. I
mean it helped me, but I was driven because I wanted
to live longer, you know. I mean, that’s why I come
to see the doctor and that. (56-year-old straight His-
panic man)
Personally, for me, the gift card was just another …
kind of the icing on the cake. I’m the kind of person
that I’m… I’m concerned about my health. I’m going
to take care of me…. [That] didn’t change, because I
know that I have no choice, and I love myself, and
I’m going to do what I need to do for myself. (66-
year-old gay Black man)
A few in the Maintenance Group (n = 5) expressed
some reservation about FIs. For example, one participant in
this group worried that ‘Not all people do the right thing
with the money that they do get. You know, they do drugs,
so …’, while another worried that FIs might ‘create a
division’ between those who can and cannot reduce their
VL.
Relapse
Only two participants had VL suppression at baseline and
did not have sustained VS during study follow-up. In
addition, 16 participants who were currently in the Low
Adherence, Action or Maintenance Groups described
relapse in adherence prior to joining the study. More than
half (n = 10) had been diagnosed and began treatment
prior to 2007—most, very early in the epidemic. The rea-
sons for relapse included incarceration or homelessness,
drug addiction (crack or crystal meth), excessive alcohol
use, and lack of health insurance or money for day to day
needs.
I was taking my medication when I was incarcerated.
Then when I came home, I actually stopped. I was
taking them here and there, but I was at a [place]
where I didn’t have my own place. I was going from
house to house, street to street, bench to bench […] I
didn’t want people I was living with to find out, so I
end up doing the rest of my jail time for violating
probation, so I end up going back to jail. I didn’t take
no medication at the time ‘cause I was just too
embarrassed at the time to take my medication […]
And I think my last bit when I did, I came home and
that’s when I actually started volunteering for Whit-
man Walker, truthfully. So they had a program at the
time where they was holding my medication. I come
here and take my medications. […] So while I was
volunteering to come here doing that, that’s when my
CD4 count starts to actually going up but then it went
down again ‘cause I didn’t (get) incarcerated but I
just started being depressed because I was still (go-
ing) from house to house, program to program at the
time. (31-year-old gay man whose race was not
reported)
About half of participants who reported previous relapse
in adherence (n = 9) attributed it to a willful decision to
stop taking the medications—either because of side effects
or because the individual couldn’t see how the medications
were helping. Reflecting back to those periods of time,
several described themselves as ‘‘becoming my own doc-
tor.’’ Often, a decline in health status led them to begin
taking their medications again.
Finally, a few participants admitted that the end of the
gift card program itself led to a relapse. For example, a
22-year-old straight Black woman stated:
Yeah, it (the gift card program) was effective for me,
because, you know, it does bring you up a little bit,
you know. But it stopping… actually, when it stop-
ped, I stopped my medication. I’m going to be honest.
I stopped for a couple of months because I was
having… it felt like that stopped, and then I had
insurance problems.
Discussion
Our sub-study provided an in-depth understanding of the
patterns of medication adherence experienced by patients
participating in an FI intervention, including their per-
spectives on the role that FIs played in promoting or sus-
taining their adherence. Over a third of sub-study
participants were already on ART, were VS upon entering
and maintained VS throughout the FI intervention. Simi-
larly, three-fourths of those who were ART naı̈ve at
baseline maintained 100% VS throughout the study.
Although generally appreciated, the FIs appeared to have
little impact on the adherence-related motivations and
behaviors of this group. For others who were on treatment
but unsuppressed at baseline, or were ART-naı̈ve but
unable to maintain VS throughout the study, FIs provided
the additional ‘‘nudge’’ needed for many to better integrate
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behaviors that would help them become and remain ‘‘un-
detectable’’. However, the FIs were insufficient to help a
small group of Low Adherers to overcome adherence
barriers.
Participants described a range of barriers to medication
adherence, including those related to the medication regi-
men itself, as well as psychological, social and structural
barriers. Across the Maintenance, Action and Low Adherer
groups, participants differed in how they confronted bar-
riers and made use of facilitators. They also differed in how
they viewed the FI program and its effect on their
adherence.
Fear of health-related side effects played a strong role in
delaying (pre-contemplation) or temporarily stopping (re-
lapse) treatment. While pill regimens have become much
simpler, participants across the three sub-study stages
described some difficulties with daily pill-taking due at
times to the specific regimens. Unlike those in the Low
Adherence Group, many participants in the Action Group
actively worked to overcome their barriers by adjusting the
timing or the way they took their medication and, if
missing an occasional pill or two, recommitting themselves
to pill taking. Maintainers appeared to have fully routinized
their pill-taking regimens and rarely let life circumstances
get in the way of pill-taking routines. These findings are
consistent with other studies that attributed early discon-
tinuation of ART regimens to intolerance or toxicity con-
cerns [28], or found that characteristics of the medication
regimen including dosing frequency, pill burden and type
of ART were correlated with medication adherence [5, 29].
Psychosocial factors appeared to play a bigger role than
medication-specific concerns in non-adherence. For those
whowere in the LowAdherenceGroup, pill-takingwas often
a reminder of their HIV status and how they got HIV. Such
reminders led some in this group tomiss pills or to stop taking
their pills altogether. In a recent meta-analysis of potential
predictors and correlates of ART adherence concluded that
psychological factors were a stronger predictor of adherence
than dosing regimen [5]. Psychosocial factors including
HIV-related stigma, anxiety, depression and stress have been
associated with low adherence to medication [30–33],
including among adolescents [31], HIV sero-discordant
couples [34] and women and minorities [35]. In our study, it
is interesting to note that the Low Adherence Group con-
sisted of a higher proportion of women and four of seven
participants who were diagnosed as children.
Several authors have argued that the field of HIV treat-
ment has not paid sufficient attention to structural issues—
either from theoretical or empirical perspectives [36–39].
Indeed, in our study structural barriers, including lack of
employment, drug and alcohol addiction, incarceration and
periods of homelessness also emerged as important reasons
for non-adherence and relapse. Suggestive of these barriers,
sub-study participants in the Low Adherence Group had
lower levels of education and income; several described
ongoing struggles with alcohol or drug addiction. Incarcer-
ation, periods of homelessness and lack of health insurance
were also experienced by participants in the Action and
Maintenance Groups, although most often when describing
initial delays in treatment or periods of non-use in the past.
Having traversed such difficult periods became a source of
power for some.
In this study, FIs were delivered within clinic settings
that offered additional supports, including information
about VL, strategies to routinize pill-taking behavior, and
medical services to address mental and physical health
issues. The role of adherence facilitators, including FIs,
varied across the SOC continuum. Participants in all three
groups (Maintenance, Action and Low Adherer) described
making changes to their daily routines and use of adher-
ence aides, including pill boxes and alarms. However,
those in the Action Group were more likely to describe an
active role—in filling their own pillboxes or making
adjustments to their pill-taking routines—than participants
in the other two groups. Similarly, the Action Group drew a
more explicit connection between receiving FIs and dou-
ble-checking whether they had taken their pills. In contrast,
the FI was not seen as necessary to those in the Mainte-
nance Group to incentivize a behavior that they already had
squarely under their control. Among the Low Adherence
Group, support from clinic providers and others to educate,
strategize and overcome other health challenges appeared
critical. The amount of the FI offered through the HPTN
065 study was not considered sufficient by some in the
Low Adherence Group to overcome the significant barriers
to adherence they faced. This finding was similar to a 2013
feasibility study, in which VS increased for those with
previous detectable VLs from 57 to 69%, but there was no
impact on those who had never achieved suppression prior
to the intervention, which suggests that the amount of the
incentive was not adequate to merit behavior change [40].
Our sub-study findings also align with the conclusions of
the HPTN 065 main study, which found that FIs increased
VS by approximately 4% at sites that offered them, but
higher (5%) among patients not consistently VS prior to
study enrollment [25].
This sub-study has several limitations. First, an indi-
vidual’s stage of change is typically assessed using a
standardized questionnaire that evaluates his/her readiness
to change [12]. Because our sub-study did not administer a
structured SOC tool to assess participants’ attitudes
towards ART medication adherence, we used an outcome
measure—the percent of VL tests identified as virally
suppressed—applied retrospectively to categorize our
study population into SOC-like stages. Nevertheless, the
categorization allowed us to examine and compare the self-
AIDS Behav (2018) 22:245–257 255
123
reported influence that individual, social and structural
factors, including offering an FI, had on achieving and
maintaining VS. Second, almost half of our sample had
long-term experience taking ART and entered the study
with a history of VS. Consequently, the role of FIs may be
less important to this group. Furthermore, their recall of
adherence-related barriers may have decreased with time.
Nevertheless, the group of long-term ART users does
provide a useful contrast by which to examine the attitudes
and behaviors of those who were unsuppressed or new to
ART at the beginning of the study. Finally, taken as a
whole, this qualitative sub-study provides an in-depth
understanding of adherence-related barriers faced by
patients at different stages of ART adherence, of the
strategies they use to facilitate ART adherence and the role
that FI play in adherence support.
Conclusion
FI effectiveness may vary across the SOC continuum. FIs
may have greatest impact for those who are ART naı̈ve or
have not yet formed explicit adherence routines or habits,
such as those in our Action Group. FIs may be insufficient on
their own to overcome adherence lapses when strong social
or structural barriers are present however, their use as part of
comprehensive care strategies that provide broader mental
health, economic and social services could prove effective
and should be further researched. Finally, FIs are probably
unnecessary for those who have strong intrinsic motivations
and well-integrated habits to support adherence.
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